Littérature scientifique sur le sujet « Sickle cell disease, Cardiomyopathy »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Sickle cell disease, Cardiomyopathy ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Sickle cell disease, Cardiomyopathy"
Niss, Omar, Charles T. Quinn, Adam Lane, Joshua Daily, Philip R. Khoury, Nihal Bakeer, Thomas R. Kimball, Jeffrey A. Towbin, Punam Malik et Michael D. Taylor. « Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease ». JACC : Cardiovascular Imaging 9, no 3 (mars 2016) : 243–52. http://dx.doi.org/10.1016/j.jcmg.2015.05.013.
Texte intégralPalomarez, Alexis, Manisha Jha, Ximena Medina Romero et Renita E. Horton. « Cardiovascular consequences of sickle cell disease ». Biophysics Reviews 3, no 3 (septembre 2022) : 031302. http://dx.doi.org/10.1063/5.0094650.
Texte intégralHammoudi, Nadjib, François Lionnet, Alban Redheuil et Gilles Montalescot. « Cardiovascular manifestations of sickle cell disease ». European Heart Journal 41, no 13 (21 avril 2019) : 1365–73. http://dx.doi.org/10.1093/eurheartj/ehz217.
Texte intégralDesai, Ankit A., Amit R. Patel, Homaa Ahmad, John V. Groth, Thejasvi Thiruvoipati, Kristen Turner, Chattanong Yodwut et al. « Mechanistic Insights and Characterization of Sickle Cell Disease–Associated Cardiomyopathy ». Circulation : Cardiovascular Imaging 7, no 3 (mai 2014) : 430–37. http://dx.doi.org/10.1161/circimaging.113.001420.
Texte intégralSachdev, Vandana, Matthew Hsieh, Neal Jeffries, Anna Noreuil, Wen Li, Stanislav Sidenko, Hwaida Hannoush et al. « Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease ». Blood Advances 3, no 19 (2 octobre 2019) : 2816–24. http://dx.doi.org/10.1182/bloodadvances.2019000387.
Texte intégralGinwalla, Mahazarin, Abdullah AlMasoud, David Tofovic, Tara Alin, Sadeer Al-Kindi, Guilherme Oliveira, Sanjay Rajagopalan, Robert Schilz et Jane Little. « Cardiovascular evaluation and management of iron overload cardiomyopathy in sickle cell disease ». American Journal of Hematology 93, no 1 (23 octobre 2017) : E7—E9. http://dx.doi.org/10.1002/ajh.24924.
Texte intégralFederti, Enrica, Iana Iatcenko, Alessandra Ghigo, Alessandro Mattè, Veronica Riccardi, Immacolata Andolfo, Angela Siciliano et al. « Colchicine Protects Against Cardiomyopathy in Humanized Mouse Model for Sickle Cell Disease ». Blood 140, Supplement 1 (15 novembre 2022) : 2513–14. http://dx.doi.org/10.1182/blood-2022-163037.
Texte intégralBlinder, Morey A., Francis Vekeman, Alex Trahey, Medha Sasane, Carole S. Paley et Mei Sheng Duh. « Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications ». Blood 118, no 21 (18 novembre 2011) : 12. http://dx.doi.org/10.1182/blood.v118.21.12.12.
Texte intégralNeumayr, Lynne, Ellen Fung, Paul Harmatz, Ellen Butensky, John Wood, Claudia Morris, Shanda Robertson, Meredith Milet et Elliott Vichinsky. « Left Ventricular Dysfunction in Chronically Transused Patients with Sickle Cell Anemia and Thalassemia. » Blood 108, no 11 (16 novembre 2006) : 3745. http://dx.doi.org/10.1182/blood.v108.11.3745.3745.
Texte intégralKamdar, Manali K., et Darla K. Liles. « Sudden Death in Adult Sickle Cell Patients : A Single Institutional Experience ». Blood 118, no 21 (18 novembre 2011) : 1061. http://dx.doi.org/10.1182/blood.v118.21.1061.1061.
Texte intégralThèses sur le sujet "Sickle cell disease, Cardiomyopathy"
Tozatto, Maio Karina. « Immunogenetics in sickle cell disease ». Thesis, Sorbonne Paris Cité, 2019. http://www.theses.fr/2019USPCC093.
Texte intégralSickle cell disease (SCD) is the most common inherited hemoglobinopathy, caused by a single nucleotide polymorphism (SNP) in the beta-globin (HBB) gene. This SNP determines the synthesis of S haemoglobin (HbS), which polymerizes under stress conditions, sickling the red blood cell (RBC). Sickle RBC are less deformable, more adherent to the endothelium, and more susceptible to haemolysis. SCD complications are explained by the interaction between haemolysis, vaso-occlusion and inflammatory activation, determined by the RBC sickling. Patients with SCD may present several complications, affecting all organs. Clinical presentation is very heterogeneous, ranging from patients who have mild symptoms to patients who die from disease complications. Because inflammation plays a major role in SCD, polymorphisms in inflammatory genes are potential targets to explain this heterogeneity. Haematopoietic stem cell transplantation (HSCT) is the only curative therapy currently available for SCD, with good results shown after human leukocyte antigen (HLA) identical sibling HSCT. However, most patients will not have a matched sibling donor. Patients with SCD are mostly from African origin, the less represented ethnic group in stem cell donor registries. To date, few studies using local registries were performed to find the probability of having a potential unrelated donor in SCD settings. This study aimed to assess the role of inflammatory genes encoding Toll-like receptors (TLR) in the occurrence of bacterial infections in patients with SCD, because infection is a leading cause of mortality in SCD, and TLR recognize a wide range of bacteria. Patients included had DNA samples and clinical data available. SNPs were genotyped by real-time polymerase chain reaction (RT-PCR). Four hundred thirty patients, mostly from Brazilian and Sub-Saharan African origin, were divided in two groups: infected (n=235, patients who presented at least one episode of bacterial infection), and non-infected (n=195, patients who never presented bacterial infections). The T/A genotype of SNP rs4696480 in TLR2 was less frequent in infected patients (50% versus 67%, OR=0.50, 95% CI 0.34-0.75, p<0.001). In addition, the T/T genotype of this SNP was more frequent among infected patients (15% versus 5%, OR=0.50, 95% CI 0.34-0.75, p<0.001). Previous reports in other settings showed that A/A carriers had higher secretion of inflammatory markers, while T allele was associated with less occurrence and severity of inflammatory diseases. Hence, T/A genotype might express the ideal inflammatory response to defeat bacteria, while the weaker inflammatory response determined by the T/T genotype increases susceptibility to bacterial infections in SCD settings
A doença falciforme (DF) é a hemoglobinopatia hereditária mais frequente, causada por um polimorfismo de nucleotídeo único (SNP) no gene da betaglobina (HBB). A ocorrência desse SNP determina a síntese de hemoglobina S, que polimeriza sob condições de stress, alterando a conformação das hemácias, que adquirem forma de drepanócitos. Os drepanócitos são menos deformáveis, mais aderentes ao endotélio e mais suscetíveis à hemolise. As complicações clínicas da DF podem ser explicadas pela interação entre a vasoclusão, hemólise e ativação inflamatória resultantes da presença dos drepanócitos na circulação. Os pacientes com DF podem apresentar numerosas complicações, que afetam todos os órgãos. A apresentação clínica da DF é muito heterogênea, variando de pacientes pouco sintomáticos a pacientes que falecem por complicações da doença. Visto que a inflamação tem um papel importante na fisiopatologia da DF, polimorfismos em genes inflamatórios poderiam explicar essa heterogeneidade.O transplante de células tronco hematopoiéticas (TCPH) é a única terapia curativa disponível atualmente para a DF, com bons resultados demonstrados em TCPH de doador aparentado antígeno leucocitário humano (HLA) idêntico. Não obstante, a maioria dos pacientes não dispõe de doador aparentado HLA idêntico. A DF ocorre em pacientes normalmente de origem africana, o grupo étnico menos representado em registro de doadores de células tronco. Nos dias de hoje, poucos estudos, utilizando registros locais, avaliaram a probabilidade de encontrar potenciais doadores não aparentados para pacientes com DF. Este estudo teve por objetivo avaliar o papel de genes inflamaórios que codificam receptores Toll-like (TLR) na ocorrência de infecções bacterianas em pacientes com DF, visto que infecção é uma das principais causas de mortalidade em DF, e os TLR reconhecem diversos tipos de bactérias. Os pacientes incluídos no estudo tinham amostras de DNA e dados clínicos disponiveis. Os SNPs foram genotipados por reação em cadeia de polimerase em tempo real (RT-PCR). Quatrocentos e trinta pacientes, a maioria de orgem brasileira ou africana subsaariana, foram divididos em dois grupos, infectados (n=235, pacientes que apresentaram ao menos um episodio de infecção bacteriana), e não infectados (n=195, pacientes que nunca tiveram tais infecções). O genótipo T/A do SNP rs4696480 foi menos frequente em pacientes infectados (50% versus 67%, OR=0.50, 95% CI 0.34-0.75, p<0.001). Além disso, o genótipo T/T do mesmo SNP foi mais frequente em pacientes infectados (15% versus 5%, OR=0.50, 95% CI 0.34-0.75, p<0.001). Estudos prévios mostraram que indivíduos com genótipo A/A apresentavam mais secreção de marcadores inflamatórios, enquanto o alelo T foi associado a menor ocorrência e menor gravidade de doenças inflamatórias
Hays, Mary Margaret. « Stem cell transplant for sickle cell disease ». Thesis, Boston University, 2013. https://hdl.handle.net/2144/12117.
Texte intégralBackground: Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. As SCD can cause significant morbidity and decrease in life expectancy, further research on curative options is of great interest. Hematopoietic stem cell transplant (HSCT) is the only treatment option offering a chance of cure, but the risks of treatment are not negligible. Because the outcomes of HSCT are best when the procedure is performed at a younger age, understanding what parents know about transplant, their opinion on this option and the risks they are willing to take to achieve a cure is of great value. As sickle cell disease has changed in the United States from a life-threatening condition of childhood to a chronic condition with most of the burden of morbidity and mortality shifted towards adulthood, it is necessary for parents to be fully aware of long term risks and educated on all therapeutic options, so the optimal decision can be made. Objectives: (i) To learn about parents’ recollection and pursuit of further information after undergoing an educational session on risks and benefits of HSCT. (ii) To learn about their worries about transplant and the highest mortality and infertility risks they are willing to accept in order to achieve a cure for their child. (iii) To learn about parents’ readiness to proceed to transplant based on a hypothetical scenario. [TRUNCATED]
Kawadler, J. M. « Neuroimaging biomarkers in paediatric sickle cell disease ». Thesis, University College London (University of London), 2015. http://discovery.ucl.ac.uk/1464063/.
Texte intégralGavlak, J. C. D. « Sleep in children with sickle cell disease ». Thesis, University College London (University of London), 2016. http://discovery.ucl.ac.uk/1528622/.
Texte intégralGardner, Catherine Joanne. « Genotype-phenotype correlation in sickle cell disease ». Thesis, King's College London (University of London), 2017. https://kclpure.kcl.ac.uk/portal/en/theses/genotypephenotype-correlation-in-sickle-cell-disease(07a190be-c88a-41f2-8e74-e063d85919a3).html.
Texte intégralEdmond, A. M. « The spleen in sickle cell disease in childhood ». Thesis, University of Cambridge, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.598759.
Texte intégralSinghal, Atul. « Growth and metabolism in homozygous sickle cell disease ». Thesis, University College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.288009.
Texte intégralIndik, Julia H., Vineet Nair, Ruslan Rafikov, Iwan S. Nyotowidjojo, Jaskanwal Bisla, Mayank Kansal, Devang S. Parikh et al. « Associations of Prolonged QTc in Sickle Cell Disease ». PUBLIC LIBRARY SCIENCE, 2016. http://hdl.handle.net/10150/622120.
Texte intégralJÃnior, Geraldo Bezerra da Silva. « Renal abnormalities in patients with sickle cell disease ». Universidade Federal do CearÃ, 2013. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=10491.
Texte intégralABSTRACT Background - Kidney abnormalities are one of the main chronic complications of sickle cell disease (SCD). The aim of this study is to investigate the occurrence of renal abnormalities among patients with SCD. Methods - This is a cohort study with 26 SCD patients followed in a medical center in Fortaleza, CearÃ, Brazil. Urinary acidification and concentration tests were performed using calcium chloride (CaCl2), and after a 12h period of water and food deprivation. Fractional excretion of sodium (FENa), transtubular potassium gradient (TTKG) and solute free water reabsorption (TcH2O) were calculated. The SCD group was compared to a group of 15 healthy volunteers (control group). Aquaporin-2 (AQP2) and renal outer medullary K+ channels (ROMK) were quantified through exosomes search in urine. Results - Patient`s average age and gender were similar to controls. Urinary acidification deficit was found in 5 SCD patients (19.2%), who presented urinary pH > 5.5 after CaCl2 test. Urinary osmolality was significantly lower in SCD patients (355Â60 vs. 818Â202mOsm/kg, p=0.0001, after 12h period water deprivation). Urinary concentration deficit was found in all SCD patients (100%). FENa was higher among SCD patients (0.75Â0.3 vs. 0.55Â0.2%, p=0.02). The TTKG was higher in SCD patients (5.5Â2.5 vs. 3.0Â1.5, p=0.001), and TcH2O was lower (0.22Â0.3 vs. 1.1Â0.3L/day, p=0.0001). The search for AQP2 did not show significant difference between SCD patients and control group (102Â6.0 vs. 100Â7.2%, p=0.874), as well as for ROMK (172Â38 vs. 100Â25%, p=0.207). Conclusions - SCD is associated with important kidney dysfunction. The main abnormalities found were urinary concentrating and incomplete distal acidification defect. There was also an increase in the potassium transport and decrease in water transport, evidencing the occurrence of distal tubular dysfunction.
RESUMO IntroduÃÃo - AlteraÃÃes renais representam uma das complicaÃÃes crÃnicas principais da doenÃa falciforme (DF). O objetivo deste estudo à investigar a ocorrÃncia de alteraÃÃes renais em pacientes com DF. MÃtodos - Foi realizado estudo de coorte com 26 pacientes com DF acompanhados em um ambulatÃrio de Fortaleza, CearÃ, Brasil. Testes de acidificaÃÃo e concentraÃÃo urinÃrias foram realizados usando cloreto de cÃlcio (CaCl2) e apÃs perÃodo de 12h de jejum e privaÃÃo hÃdrica. Foram calculados fraÃÃo de excreÃÃo de sÃdio (FENa), transporte transtubular de potÃssio (TTKG) e transporte de Ãgua livre de solutos (TcH2O). O grupo de pacientes com DF foi comparado com um grupo de 15 voluntÃrios sadios (grupo controle). Os transportadores aquaporina-2 (AQP2) e canal de K+ apical (ROMK) foram quantificados pela pesquisa de exossomas na urina. Resultados - A mÃdia de idade e a distribuiÃÃo de gÃnero foi similar entre os dois grupos. DÃficit de acidificaÃÃo urinÃria foi encontrada em 5 pacientes com DF (19,2%), que apresentaram pH urinÃrio > 5,5 apÃs o teste com CaCl2. A osmolaridade urinÃria foi significativamente menor entre os pacientes com DF (355Â60 vs. 818Â202mOsm/kg, p=0,0001, apÃs perÃodo de 12h de jejum e privaÃÃo hÃdrica). DÃficit de concentraÃÃo urinÃria foi encontrado em todos os casos de DF (100%). A FENa foi maior entre os pacientes com DF (0,75Â0,3 vs. 0,55Â0,2%, p=0,02). O TTKG tambÃm foi maior nos pacientes com DF (5,5Â2,5 vs. 3,0Â1,5, p=0,001), e o TcH2O foi menor (0,22Â0,3 vs. 1,1Â0,3L/dia, p=0,0001). A pesquisa de AQP2 nÃo mostrou diferenÃa significativa em relaÃÃo ao grupo controle (102Â6,0 vs. 100Â7,2%, p=0,874), bem como a do canal ROMK (172Â38 vs. 100Â25%, p=0,207). ConclusÃo - A DF à associada a importantes alteraÃÃes renais. As principais alteraÃÃes encontradas foram dÃficit de concentraÃÃo e acidificaÃÃo urinÃria. Foi ainda observado aumento no transporte
Wu, Li-Chen. « Correction of sickle cell disease by homologous recombination ». Thesis, Birmingham, Ala. : University of Alabama at Birmingham, 2008. https://www.mhsl.uab.edu/dt/2008p/wu.pdf.
Texte intégralLivres sur le sujet "Sickle cell disease, Cardiomyopathy"
Peak, Lizabeth. Sickle cell disease. Detroit : Lucent Books, 2008.
Trouver le texte intégralPeak, Lizabeth. Sickle cell disease. Detroit : Lucent Books, 2008.
Trouver le texte intégralSerjeant, Graham R. Sickle cell disease. 2e éd. Oxford : Oxford University Press, 1992.
Trouver le texte intégralSickle cell disease. Oxford : Oxford University Press, 1985.
Trouver le texte intégralF, Whitten Charles, Bertles John F. 1925-, National Association for Sickle Cell Disease (U.S.) et New York Academy of Sciences., dir. Sickle cell disease. New York, N.Y : New York Academy of Sciences, 1989.
Trouver le texte intégralSickle cell disease. 2e éd. Oxford : Oxford University Press, 1992.
Trouver le texte intégralSamuel, Charache, et Johnson Cage S, dir. Sickle cell disease. Philadelphia : W.B. Saunders, 1996.
Trouver le texte intégralEboh, Winifred Oluchukwu. Sickle cell disease. (Birmingham) : Birmingham Sickle Cell & Thalassaemia Centre, 1993.
Trouver le texte intégralJones, Phill. Sickle cell disease. New York : Chelsea House, 2008.
Trouver le texte intégralMcCormick, Marie, Henrietta Awo Osei-Anto et Rose Marie Martinez, dir. Addressing Sickle Cell Disease. Washington, D.C. : National Academies Press, 2020. http://dx.doi.org/10.17226/25632.
Texte intégralChapitres de livres sur le sujet "Sickle cell disease, Cardiomyopathy"
Mallouh, Ahmad A. « Sickle Cell Disease ». Dans Textbook of Clinical Pediatrics, 3005–22. Berlin, Heidelberg : Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_324.
Texte intégralKashani, John, Richard D. Shih, Thomas H. Cogbill, David H. Jang, Lewis S. Nelson, Mitchell M. Levy, Margaret M. Parker et al. « Sickle Cell Disease ». Dans Encyclopedia of Intensive Care Medicine, 2075–77. Berlin, Heidelberg : Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_342.
Texte intégralFischer, Matt, Harsh Sachdeva et Alaa Abd-Elsayed. « Sickle Cell Disease ». Dans Pain, 1279–81. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-99124-5_274.
Texte intégralRoth, Elliot J. « Sickle-Cell Disease ». Dans Encyclopedia of Clinical Neuropsychology, 3180–81. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_2197.
Texte intégralChaudhury, Sonali, et Shalini Shenoy. « Sickle cell disease ». Dans Clinical Manual of Blood and Bone Marrow Transplantation, 236–45. Chichester, UK : John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119095491.ch27.
Texte intégralGlassberg, Jeffrey, et Michael R. DeBaun. « Sickle Cell Disease ». Dans Respiratory Medicine, 131–38. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43447-6_11.
Texte intégralOrellana, Juan, et Alan H. Friedman. « Sickle Cell Disease ». Dans Clinico-Pathological Atlas of Congenital Fundus Disorders, 101–4. New York, NY : Springer New York, 1993. http://dx.doi.org/10.1007/978-1-4613-9320-7_19.
Texte intégralRoth, Elliot J. « Sickle-Cell Disease ». Dans Encyclopedia of Clinical Neuropsychology, 1–2. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-56782-2_2197-2.
Texte intégralHood, Anna M., Emily A. McTate, Naomi E. Joffe et Lori E. Crosby. « Sickle Cell Disease ». Dans Clinical Handbook of Psychological Consultation in Pediatric Medical Settings, 341–54. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-35598-2_26.
Texte intégralHyacinth, Hyacinth I., et Robert J. Adams. « Sickle Cell Disease ». Dans Stroke Genetics, 135–61. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56210-0_9.
Texte intégralActes de conférences sur le sujet "Sickle cell disease, Cardiomyopathy"
Glas-Greenwalt, P., J. Palascak, R. Gruppo, D. Stroop et V. Pollak. « DEFECTIVE FIBRINOLYSIS IN SICKLE CELL DISEASE ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644838.
Texte intégralHegemann, I., et J. Sangalli-Baruffaldi. « Evaluation of thrombin generation in patients with sickle cell disease in stable disease and sickle cell crises ». Dans 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728172.
Texte intégralDautzenberg, M. D., F. Monge, A. M. Fischer, R. Girot et P. Cornu. « COAGULATION AND FIBRINOLYSIS IN SICKLE CELL DISEASE ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643056.
Texte intégralPollack, Y., E. McAllister, A. J. Dozor et S. S. Krishnan. « Ventilatory Homogeneity in Children with Sickle Cell Disease ». Dans American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4674.
Texte intégralLunt, Alan C., Alice Chubb, Swee Lay Thein, Gerrard F. Rafferty et Anne Greenough. « Impulse Oscillometry In Adults With Sickle Cell Disease ». Dans American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2179.
Texte intégralBrzoska, T., E. V. Menchikova, T. W. Kaminski, R. Vats, E. Tutuncuoglu, S. P. Tofovic, E. K. Jackson, M. T. Gladwin et P. Sundd. « Impaired Platelet Purinergic Signaling in Sickle Cell Disease ». Dans American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3300.
Texte intégralSilveira Lopes, Jordana Alícia, Daniela de Oliveira Werneck Rodrigues, Amanda do Carmo Gusmão, Augusto Cézar Apolinário dos Santos, Nathalia Noyma Sampaio Magalhães, Olivia Franco dos Santos, Renato Lourenço de Medeiros, Rodrigo de Martin Almeida, Tássia Mariana Moreira da Paz et Thaís Sette Espósito. « NEUROPATHIC PAIN AMONG PATIENTS WITH SICKLE CELL DISEASE ». Dans Congresso Brasileiro de Reumatologia 2020. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2020.17217.
Texte intégralSingh, Bikesh Kumar, et Hardik Thakkar. « Hydroxyurea Dosage Classification for Sickle Cell Disease Patients ». Dans 2021 6th International Conference on Inventive Computation Technologies (ICICT). IEEE, 2021. http://dx.doi.org/10.1109/icict50816.2021.9358788.
Texte intégralKrivinskas, S., et B. Madden. « Rigid Bronchoscopy in Patients with Sickle Cell Disease ». Dans American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1094.
Texte intégralHosseini, Poorya, Sabia Z. Abidi, Gregory J. Kato, Ming Dao, Zahid Yaqoob et Peter T. C. So. « Biophysical markers of Sickle Cell Disease at Individual Cell Level ». Dans Cancer Imaging and Therapy. Washington, D.C. : OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jtu3a.44.
Texte intégralRapports d'organisations sur le sujet "Sickle cell disease, Cardiomyopathy"
Paul, Satashree. Turning Back the Sickle Cell Disease : A New Drug into Play. Science Repository OÜ, mai 2021. http://dx.doi.org/10.31487/sr.blog.38.
Texte intégralKrishnamurti, Lakshmanan, Deepika Darbari, Victor Gordeuk, Torria Beasely, Clark Brown, Syed Nouraie et Gregory Kato. Can Personalized Encouragement Help People With Sickle Cell Disease Take Hydroxyurea Therapy Regularly ? Patient-Centered Outcomes Research Institute® (PCORI), mai 2020. http://dx.doi.org/10.25302/05.2020.ce.13046859em.
Texte intégralLanzkron, Sophie, Jane Little, Joshua Field, J. Ryan Shows, Carlton Haywood Jr, Ravi Varadhan, Mustapha Saheed et al. Comparing Pain Management for Sickle Cell Disease Crises in Emergency Rooms and Infusion Centers. Patient-Centered Outcomes Research Institute (PCORI), août 2020. http://dx.doi.org/10.25302/08.2020.ihs.140311888.
Texte intégralKrishnamurti, Lakshmanan, Diana Ross, Nitya Bakshi, Cynthia Brown Sinha et Geoerge Loewenstein. An Online Decision Aid to Help Patients and Caregivers Decide on Treatments for Sickle Cell Disease. Patient-Centered Outcomes Research Institute® (PCORI), janvier 2020. http://dx.doi.org/10.25302/1.2020.ce.12114318em.
Texte intégralMarques, Carla, Larissa Lopes, Rita Lucena et Abrahão Baptista. Brain morphofunctional changes associated with pain in children, adolescents and young adults with sickle cell disease. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, décembre 2022. http://dx.doi.org/10.37766/inplasy2022.12.0022.
Texte intégralChou, Roger, Jesse Wagner, Azrah Y. Ahmed, Ian Blazina, Erika Brodt, David I. Buckley, Tamara P. Cheney et al. Treatments for Acute Pain : A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), décembre 2020. http://dx.doi.org/10.23970/ahrqepccer240.
Texte intégralWhat support do young people with sickle cell disease need when moving into adult services ? National Institute for Health Research, juin 2021. http://dx.doi.org/10.3310/alert_46618.
Texte intégral